spot_img
Friday, August 12, 2022
More
    HomeHealthAbbVie's 'patent thickets' for Humira don't thwart competition, court rules

    AbbVie’s ‘patent thickets’ for Humira don’t thwart competition, court rules

    -



    In a big victory for AbbVie, a U.S. appeals court docket panel declined to revive a lawsuit that accused the corporate of utilizing a so-called patent thicket to forestall competitors for its Humira remedy, a franchise product that generates billions of {dollars} in gross sales every year.

    The opinion shot down arguments by unions, insurers, and the town of Baltimore, which alleged that AbbVie “abused the patent system” and “erected important boundaries to entry to dam biosimilar competitors” by submitting dozens of patents for the drug. A number of the 132 U.S. patents that the corporate holds on its drugs lengthen to 2034, though the fundamental patent expired in 2016.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,434FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts